Drug Discovery World

MARCH 15, 2024

Biotechnology company Allyx Therapeutics has reported positive Phase Ib clinical data for its lead compound, ALX-001, a first-in-class, synapse-targeted, disease-modifying oral therapy in development for neurodegenerative diseases. The findings were presented at the AD/PD 2024 Conference in Lisbon.

Disease 130

Disease Trials Small Molecule Pharmacokinetics 130

Drug Discovery World

DECEMBER 7, 2023

Inipharm has initiated Phase I dosing of its lead candidate, INI-822, which is a small-molecule inhibitor for HSD17B13, a gene implicated in nonalcoholic steatohepatitis (NASH). Loss-of-function variants of HSD17B13 are known to be associated with reduced incidence risk and severity of multiple liver diseases.

Disease 147

Disease Small Molecule Drugs Treatment 147

Drug Discovery World

SEPTEMBER 9, 2024

NRG Therapeutics has been awarded a non-dilutive grant from Target ALS Foundation to support its discovery programme for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or motor neurone disease. In diseases like ALS, mitochondria become defective, leading to brain cell death and disease progression.

Small Molecule 162

Small Molecule Clinical Trials Disease Trials 162

Drug Discovery World

OCTOBER 4, 2022

William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . With its recent award of $3.35 Overcoming sector challenges .

Disease 130

Disease Small Molecule Compound Screening Clinical Development 130

The Pharma Data

JULY 28, 2021

Novel small molecule drug candidates will target GPR75 to potentially address obesity and related co-morbidities. AstraZeneca has entered into a collaboration with Regeneron to research, develop and commercialise small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities.

Small Molecule 52

Small Molecule Research Science Disease 52

Drug Discovery Today

APRIL 20, 2023

Global integrated drug discovery company, Sygnature Discovery and global healthcare group Daewoong Pharmaceutical, have entered into a research collaboration agreement to accelerate the discovery of a novel small molecule to target autoimmune disease.

Small Molecule 113

Small Molecule Research Drugs Pharmaceuticals 113

The Pharma Data

NOVEMBER 17, 2020

Lead Pharma has entered into a collaboration and license agreement with Roche , hoping to lead the way in the development of oral small molecules for immune-mediated diseases like rheumatoid arthritis, psoriasis and inflammatory bowel diseases. . The agreement encompasses Lead Pharma’s entire pipeline.

Small Molecule 52

Small Molecule Disease Immune Response Licensing 52

Drug Discovery World

NOVEMBER 8, 2023

Over 19 million 1 hearts succumb to cardiovascular disease yearly, while around 10 million 2 lives are claimed by cancer every year. By swiftly sifting through complex datasets, AI algorithms can identify patterns, extract valuable insights, and uncover subtle correlations that might elude human researchers.

Clinical Trials 182

Clinical Trials Trials Disease Medical Schools 182

Drug Discovery World

NOVEMBER 9, 2022

The next stage will involve the identification of small molecule inhibitors to treat RSV infections. The final stage of the research plan will utilise OneThree’s AI platform to identify the drugs that are most likely to be efficacious against the identified disease targets with clean safety profiles in RSV patients. .

Disease 130

Disease Small Molecule Virus Trials 130

Drug Target Review

OCTOBER 11, 2023

Almost every one of us will know someone with a neurodegenerative disease such as Alzheimer’s or Parkinson’s. It is less common to know someone with a rare genetic disease; but while individually rare, collectively they have an enormous impact. This will, in turn, slow the progression of, or even halt, the disease.

Disease 113

Disease Treatment Small Molecule Therapies 113

Drug Discovery World

SEPTEMBER 5, 2024

SBL01 is a first-in-class small molecule ‘dual inhibitor of both necroptosis and ferroptosis’ Regulated cell death, such as necroptosis and ferroptosis, are key processes in acute liver failure where cells degenerate abruptly. This is an important recognition of our strong preclinical research dataset.

Small Molecule 147

Small Molecule Drugs Production Regulations 147

Drug Target Review

JUNE 15, 2023

In this article Drug Target Review’s Izzy Wood spoke to Sam Hasson, Director of Target Biology at Rgenta Therapeutics, a biotech firm in Massachusetts, US, that aims to develop small molecule therapeutics to target RNA processing.

RNA 96

RNA Small Molecule Disease Assay Development 96

Drug Discovery World

AUGUST 18, 2022

Artificial intelligence (AI) company Atomwise has signed an exclusive research collaboration with Sanofi to use its AtomNet?platform platform for computational discovery and research of up to five drug targets. . Subsequent payments pegged to key research, development, and sales milestones could total more than $1 billion.

Research 130

Research Small Molecule Engineering Therapies 130

Drug Target Review

JULY 13, 2023

In recent years, a novel approach known as condensate biology has emerged, revolutionising the way researchers think about drug discovery and development. He now leads research and development (R&D) at Dewpoint. Dewpoint’s breakthrough was the realisation that certain condensates are associated with human diseases.

Disease 98

Disease Small Molecule Cell Biology Medical Schools 98

Drug Discovery World

JANUARY 11, 2024

VRG50635 is a small molecule PIKfyve inhibitor and is reportedly one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platform. ” The post AI-discovered ALS drug trial uses unique remote monitoring appeared first on Drug Discovery World (DDW).

Drug Trials 246

Drug Trials Trials Small Molecule Clinical Trials 246

Dark Matter Blog

AUGUST 27, 2020

A few years ago, at Arrakis Therapeutics, we set out to conquer a strange new territory, drugging RNA structures with small molecules. The efficiency of exon 7 inclusion in the mature SMN2 mRNA varies significantly among patients and poor inclusion efficiency correlates with higher disease severity.

Small Molecule 52

Small Molecule RNA Clinical Trials Drugs 52

Collaborative Drug

AUGUST 29, 2023

a new Italian incubator dedicated to the discovery and development of small molecule-based treatments for neurodegenerative diseases, announced today that it has adopted Collaborative Drug Discovery’s CDD Vault as its platform of choice for managing drug discovery data.

Small Molecule 82

Small Molecule Treatment Disease Research 82

Drug Discovery World

MAY 30, 2024

A new research paper has validated the mechanism of action of the Atrogi’s first-in-class, small molecule, ATR-127, in combating obesity and metabolic complications. Unlike existing anti-obesity therapies that compromise lean muscle mass, ATR-127 induces significant weight loss while preserving crucial lean body mass.

Small Molecule 147

Small Molecule Treatment International Production 147

Drug Discovery World

MAY 31, 2024

The selected news highlights this week report breakthrough findings from early phase research and development, mainly preclinical studies and Phase I clinical trials, including a drug that can prevent sepsis deaths, a microbiome based immuno-oncology candidate, and a plant-based therapy for diarrhoea.

Small Molecule 130

Small Molecule Clinical Trials Drugs Trials 130

Drug Discovery World

JULY 19, 2024

The research – published in Nature Communications and led by the University of Glasgow – replicates key aspects of the human bone marrow microenvironment, to enable the support of rare long-term hematopoietic stem cells, or LT-HSCs. However, they are challenging to culture in the lab as they quickly change or die once out of the body.

Small Molecule 130

Small Molecule Drugs Engineering Disease 130

Drug Discovery World

AUGUST 4, 2022

Biopharmaceutical group Sosei will work together with AbbVie on a drug discovery project to discover, develop and commercialise small molecules that target neurological diseases. . Matt Barnes, Head of UK Research & Development, Sosei Heptares said:? “We Sosei will put forward its Heptares’? regulatory ?and

Structure Based Drug Design (SBDD) 130

Structure Based Drug Design (SBDD) Small Molecule Drugs Licensing 130

DrugBank

JULY 24, 2024

This is a game-changer, especially in the fight against cancer and other complex diseases. These multifunctional small molecules are like tiny spies, hijacking the body’s natural protein degradation system to remove unwanted proteins. This can potentially correct the root causes of some diseases at the genetic level.

Small Molecule 84

Small Molecule Clinical Trials Drugs Therapies 84

BioPharma Drive: Drug Pricing

APRIL 22, 2024

billion, is the latest research collaboration involving small molecule drugs that modify RNA. The deal, which could be worth up to $1.8

RNA 67

RNA Small Molecule Disease Research 67

Broad Institute

NOVEMBER 2, 2023

Bayer and Broad Institute extend cancer therapy research collaboration By Corie Lok November 2, 2023 Breadcrumb Home Bayer and Broad Institute extend cancer therapy research collaboration Long-standing industry-academia collaboration has already resulted in three clinical oncology candidates.

Therapies 105

Therapies Research Small Molecule Clinical Trials 105

Drug Discovery World

AUGUST 21, 2023

When they go awry, they often drive cancer and other disease processes like diabetes, inflammatory diseases, and neurological conditions. “At This funding will enable us to accelerate and optimise new molecules to address diseases that are driven by regulatory protein dysfunction,” said Talus Bio CEO and Co-Founder Alex Federation.

Small Molecule 245

Small Molecule DNA Drugs Licensing 245

DrugBank

MAY 15, 2024

Researchers would sift through natural extracts , hoping to stumble upon a compound that exhibited beneficial effects. Today, we're able to identify and target specific molecules involved in disease processes—a method that's much more like using a sniper rifle than throwing darts blindfolded.

Small Molecule 83

Small Molecule Molecular Biology Drugs Disease 83

Drug Discovery World

FEBRUARY 12, 2024

By inhibiting myofibroblasts’ deposition of extracellular matrix, the candidate demonstrates substantial potential in mitigating fibrotic diseases. Anima Biotech has identified a preclinical candidate, effectively disrupting the transformation of fibroblasts into fully differentiated myofibroblasts.

Small Molecule 130

Small Molecule Disease Therapies Production 130

Drug Discovery World

APRIL 24, 2024

Evotec and Variant Bio have announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis. Despite the chronic nature of fibrotic conditions, widespread impact on various organs, and substantial disease burden, there is currently no curative treatment for these conditions.

Treatment 130

Treatment Small Molecule Clinical Development Disease 130

Drug Discovery World

MARCH 12, 2024

Lia Sylvestri, Director Customer Experience & Engagement , TrakCel “In 2024, significant advancements in monoclonal antibodies (mAbs) research are anticipated with leading companies, such as Roche, Regeneron, and Eli Lilly, expected to drive breakthroughs in precision medicine, tailoring mAbs for diverse diseases.

Molecular Biology 204

Molecular Biology Small Molecule Therapies FDA Approval 204

New Drug Approvals

SEPTEMBER 12, 2024

Zastaprazan can be used for the research of gastrointestinal inflammatory diseases or gastric acid-related diseases. ZASTAPRAZAN 2133852-18-1 362.5 ZASTAPRAZAN 2133852-18-1 362.5

Small Molecule 57

Small Molecule Trials Disease Research 57

Drug Discovery World

AUGUST 18, 2023

My chosen news stories this week all discuss pre-clinical research studies that could have a huge impact on our therapeutic approach to several hard-to-treat diseases, helping to overcome drug-resistance and make treatments more targeted in the future.

Small Molecule 130

Small Molecule Virus Drugs Clinical Research 130

Drug Discovery World

FEBRUARY 5, 2024

Opening keynote Following a change to the schedule, Juliet Williams of Kymera Therapeutics launched the event with a popular keynote talk ‘Solving Big Problems with Small Molecule Degraders’.

Small Molecule 162

Small Molecule Assay Development Production Science 162

Drug Discovery World

JANUARY 13, 2023

The preclinical start-up is working towards the development of first-in-class small molecule inhibitors of transglutaminase 2 (TG2), one of the major crosslinking enzymes in the human body, which becomes more active during ageing, resulting in fibrotic diseases. .

Small Molecule 130

Small Molecule Treatment Disease Research 130

Drug Discovery World

FEBRUARY 28, 2023

The funding will drive proprietary research into novel compounds that extend healthy lifespan of cells and tissues, with therapeutic potential across a broad range of age-related diseases. Five Alarm Bio (FAB) has completed a seed investment round, raising over £500K ($605K).

Small Molecule 130

Small Molecule Disease Science Treatment 130

Drug Discovery World

MAY 13, 2024

Key to this is the ability to rapidly determine protein structures alone and in combination with antibodies or small molecules. Researchers are using cryo-EM to understand the structure of the hemagglutinins (HAs), which are proteins on the surface of the influenzae virus.

Vaccine 147

Vaccine Virus Small Molecule Disease 147

Drug Discovery World

MAY 26, 2023

Although Clarivate has reported a recent drop in investment in the industry, it is good to see companies raising money through funding rounds and investing in new facilities, as well as government support coming through to boost research in areas of urgent need.

Small Molecule 130

Small Molecule DNA Government RNA 130

Drug Discovery World

FEBRUARY 12, 2024

Cameron Ross, SVP, Generative AI, Elsevier “AI has the potential to dramatically shorten one of the most costly areas of early drug development – small molecule discovery. We’re already seeing biotechs making breakthroughs with AI in this area, with more than 150 small molecule drugs discovered and 15 already in clinical trials.

Small Molecule 349

Small Molecule Regulations Clinical Trials Therapies 349